Codeine and morphine in extensive and poor metabolizers of sparteine: Pharmacokinetics, analgesic effect and side effects

被引:168
|
作者
Poulsen, L
Brosen, K
ArendtNielsen, L
Gram, LF
Elbaek, K
Sindrup, SH
机构
[1] ODENSE UNIV,INST MED BIOL,DEPT CLIN PHARMACOL,DK-5000 ODENSE C,DENMARK
[2] UNIV AALBORG,CTR SENSORY MOTOR INTERACT,AALBORG,DENMARK
[3] NYCOMED PHARMA,CLIN RES & DEV,COPENHAGEN,DENMARK
关键词
CYP2D6; codeine; morphine; pharmacokinetics; analgesic effect; adverse effects;
D O I
10.1007/s002280050200
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Codeine O-demethylation to morphine is catalysed by the genetic polymorphic sparteine oxygenase (CYP2D6). The objective of the present study was to assess the analgesic effect of codeine on different types of experimental pain in relation to sparteine phenotype. Methods: Fourteen extensive (EMs) and 14 poor metabolizers (PMs) of sparteine completed a randomized, double-blind, three-way, cross-over study with a single oral dose of codeine (75 or 100 mg) against morphine (20 or 30 mg) and placebo. Pain tests performed before and 1, 2, 3, and 4 h after medication included the cold presser test and gain thresholds for heat and pressure stimulation. Adverse effects were rated by a structured interview. Results: After morphine, morphine and morphine-6-glucuronide were present in equal amounts in plasma of PMs and EMs. After codeine, neither morphine nor morphine-6-glucuronide could be detected in 13 of the 14 PMs, whereas at least one of the compounds could be detected in all EMs. Peak pain and discomfort rated on a VAS scale during the cold presser test were significantly reduced by morphine in both EMs and PMs, with a median peak change of 8.5 and 7.0 mm, respectively, for peak pain, and 11.5 and 15.5 mm, respectively, for discomfort. Codeine only reduced these pain measures significantly in EMs, with a median peak change of 5.5 mm for peak pain and 10.5 mm for discomfort. Pain detection and tolerance thresholds to heat and pressure were not consistently altered by either morphine or codeine. In PMs, adverse effects were significantly more pronounced on morphine than on codeine and only showed a slight difference between codeine and placebo. In EMs, there was no difference between codeine and morphine and more pronounced adverse effects on both drugs as compared to placebo. Conclusion. This study confirms that codeine O-demethylation depends on CYP2D6; it shows that the 6-glucuronidation of morphine is independent of CYP2D6; it supports the theory that the analgesic effect of codeine depends on its O-demethylation; and it indicates that this is probably also the case for the adverse effects. The resuls lend no support to the suggestion of a non-opioid analgesic effect of codeine.
引用
收藏
页码:289 / 295
页数:7
相关论文
共 50 条
  • [1] PHARMACOKINETICS AND METABOLISM OF QUINIDINE IN EXTENSIVE AND POOR METABOLIZERS OF SPARTEINE
    MIKUS, G
    HA, HR
    VOZEH, S
    ZEKORN, C
    FOLLATH, F
    EICHELBAUM, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (01) : 69 - 72
  • [2] ENDOGENOUS CODEINE AND MORPHINE IN POOR AND EXTENSIVE METABOLIZERS OF THE CYP2D6 (DEBRISOQUINE/SPARTEINE) POLYMORPHISM
    MIKUS, G
    BOCHNER, F
    EICHELBAUM, M
    HORAK, P
    SOMOGYI, AA
    SPECTOR, S
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1994, 268 (02): : 546 - 551
  • [3] CODEINE INCREASES PAIN THRESHOLDS TO COPPER VAPOR LASER STIMULI IN EXTENSIVE BUT NOT POOR METABOLIZERS OF SPARTEINE
    SINDRUP, SH
    BROSEN, K
    BJERRING, P
    ARENDTNIELSEN, L
    LARSEN, U
    ANGELO, HR
    GRAM, LF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (06) : 686 - 693
  • [4] The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
    Fjordside, L
    Jeppesen, U
    Eap, CB
    Powell, K
    Baumann, P
    Brosen, K
    PHARMACOGENETICS, 1999, 9 (01): : 55 - 60
  • [5] The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
    Fjordside, L
    Jeppesen, U
    Eap, CP
    Powell, K
    Baumann, P
    Brosen, K
    NORDIC JOURNAL OF PSYCHIATRY, 1998, 52 (02) : 113 - 114
  • [6] METABOLISM OF ALMITRINE IN EXTENSIVE AND POOR METABOLIZERS OF DEBRISOQUINE SPARTEINE
    HERCHUELZ, A
    GANGJI, D
    DERENNE, F
    JEANNIOT, JP
    DOUCHAMPS, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (01) : 73 - 76
  • [7] ARE POOR METABOLIZERS OF SPARTEINE DEBRISOQUINE LESS PAIN TOLERANT THAN EXTENSIVE METABOLIZERS
    SINDRUP, SH
    POULSEN, L
    BROSEN, K
    ARENDTNIELSEN, L
    GRAM, LF
    PAIN, 1993, 53 (03) : 335 - 339
  • [8] INHIBITION BY PAROXETINE OF DESIPRAMINE METABOLISM IN EXTENSIVE BUT NOT IN POOR METABOLIZERS OF SPARTEINE
    BROSEN, K
    HANSEN, JG
    NIELSEN, KK
    SINDRUP, SH
    GRAM, LF
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (04) : 349 - 355
  • [9] ANALGESIC EFFECT AND SIDE EFFECT LIABILITY OF DIHYDROCODEINE, CODEINE AND MORPHINE IN MAN
    BEECHER, HK
    GRAVENSTEIN, JS
    PEDERSON, DP
    SMITH, GM
    FEDERATION PROCEEDINGS, 1957, 16 (01) : 281 - 281
  • [10] PHARMACOKINETICS AND BETA-BLOCKING EFFECTS OF TIMOLOL IN POOR AND EXTENSIVE METABOLIZERS OF DEBRISOQUIN
    MCGOURTY, JC
    SILAS, JH
    FLEMING, JJ
    MCBURNEY, A
    WARD, JW
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (04) : 409 - 413